TG Therapeutics (TGTX)

• Market cap: $5.01B
• 1 day: -0.31%
• 5 days: -3.86%
• 1 month: -7.08%
• 3 months: 37.97%
• 6 months: 74.69%
• Year to date: 88.73%
• 1 year: 89.29%
• 5 years: 187.14%
• 10 years: 100.62%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

Employees: 319

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 96 | Existing positions closed: 48

52% more call options, than puts

Call options by funds: $70.9M | Put options by funds: $46.8M

40% more capital invested

Capital invested by funds: $1.69B [Q2] → $2.36B (+$671M) [Q3]

28% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 72

19% more funds holding

Funds holding: 254 [Q2] → 302 (+48) [Q3]

3.92% more ownership

Funds ownership: 61.34% [Q2] → 65.26% (+3.92%) [Q3]

17% less funds holding in top 10

Funds holding in top 10: 6 [Q2] → 5 (-1) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $22 32% downside
• Avg. target: $43 32% upside
• High target: $55 71% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

JP Morgan Eric Joseph 52% 1-year accuracy 15 / 29 met price target	34% upside $43	Overweight Maintained	25 Nov 2024
HC Wainwright & Co. Edward White 24% 1-year accuracy 33 / 140 met price target	71% upside $55	Buy Maintained	5 Nov 2024
Goldman Sachs Corinne Jenkins 36% 1-year accuracy 4 / 11 met price target	32% downside $22	Neutral Maintained	5 Nov 2024
TD Cowen Tara Bancroft 50% 1-year accuracy 2 / 4 met price target	55% upside $50	Buy Initiated	29 Oct 2024